Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance, Shares at Dec. 31, 2023		203,415,024
Beginning balance at Dec. 31, 2023		$ 383,902
Beginning balance, Shares at Dec. 31, 2023			2,385,212
Beginning balance at Dec. 31, 2023	$ (373,848)		$ 2	$ 21,836	$ (395,686)
Exercise of stock options, Shares			30,083
Exercise of stock options	365			365
Issuance of restricted stock, Shares			10
Vesting of restricted stock and early exercised stock options	11			11
Stock-based compensation expense	2,310			2,310
Net income (loss) and comprehensive income (loss)	(32,494)				(32,494)
Ending balance, Shares at Mar. 31, 2024		203,415,024
Ending balance at Mar. 31, 2024		$ 383,902
Ending balance, Shares at Mar. 31, 2024			2,415,305
Ending balance at Mar. 31, 2024	(403,656)		$ 2	24,522	(428,180)
Beginning balance, Shares at Dec. 31, 2023		203,415,024
Beginning balance at Dec. 31, 2023		$ 383,902
Beginning balance, Shares at Dec. 31, 2023			2,385,212
Beginning balance at Dec. 31, 2023	(373,848)		$ 2	21,836	(395,686)
Net income (loss) and comprehensive income (loss)	106,562
Ending balance, Shares at Jun. 30, 2024		203,415,024
Ending balance at Jun. 30, 2024		$ 383,902
Ending balance, Shares at Jun. 30, 2024			2,423,862
Ending balance at Jun. 30, 2024	(262,373)		$ 2	26,749	(289,124)
Beginning balance, Shares at Mar. 31, 2024		203,415,024
Beginning balance at Mar. 31, 2024		$ 383,902
Beginning balance, Shares at Mar. 31, 2024			2,415,305
Beginning balance at Mar. 31, 2024	(403,656)		$ 2	24,522	(428,180)
Exercise of stock options, Shares			8,555
Exercise of stock options	79			79
Issuance of restricted stock, Shares			2
Vesting of restricted stock and early exercised stock options	6			6
Stock-based compensation expense	2,142			2,142
Net income (loss) and comprehensive income (loss)	139,056				139,056
Ending balance, Shares at Jun. 30, 2024		203,415,024
Ending balance at Jun. 30, 2024		$ 383,902
Ending balance, Shares at Jun. 30, 2024			2,423,862
Ending balance at Jun. 30, 2024	(262,373)		$ 2	26,749	(289,124)
Beginning balance, Shares at Dec. 31, 2024		297,205,041
Beginning balance at Dec. 31, 2024	$ 508,087	$ 508,087
Beginning balance, Shares at Dec. 31, 2024	2,446,864		2,446,864
Beginning balance at Dec. 31, 2024	$ (311,183)		$ 2	47,242	(358,427)
Issuance of common stock in connection with initial public offering, net of issuance costs, Shares			8,750,000
Issuance of common stock in connection with initial public offering, net of issuance costs	124,598		$ 9	124,589
Conversion of redeemable convertible preferred stock to common stock upon initial public offering, Shares		(297,205,041)
Conversion of redeemable convertible preferred stock to common stock upon initial public offering		$ (508,087)
Conversion of redeemable convertible preferred stock to common stock upon initial public offering, Shares			32,586,823
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	508,087		$ 33	508,054
Exercise of stock options, Shares			13,479
Exercise of stock options	126			126
Stock-based compensation expense	3,226			3,226
Net income (loss) and comprehensive income (loss)	(32,786)				(32,786)
Ending balance, Shares at Mar. 31, 2025			43,797,166
Ending balance at Mar. 31, 2025	292,068		$ 44	683,237	(391,213)
Beginning balance, Shares at Dec. 31, 2024		297,205,041
Beginning balance at Dec. 31, 2024	$ 508,087	$ 508,087
Beginning balance, Shares at Dec. 31, 2024	2,446,864		2,446,864
Beginning balance at Dec. 31, 2024	$ (311,183)		$ 2	47,242	(358,427)
Net income (loss) and comprehensive income (loss)	$ (66,465)
Ending balance, Shares at Jun. 30, 2025	43,850,884		43,850,884
Ending balance at Jun. 30, 2025	$ 262,238		$ 44	687,086	(424,892)
Beginning balance, Shares at Mar. 31, 2025			43,797,166
Beginning balance at Mar. 31, 2025	292,068		$ 44	683,237	(391,213)
Issuance of common stock under the 2025 Employee Stock Purchase Plan, Shares			53,716
Issuance of common stock under the 2025 Employee Stock Purchase Plan	612			612
Issuance of restricted stock, Shares			2
Stock-based compensation expense	3,237			3,237
Net income (loss) and comprehensive income (loss)	$ (33,679)				(33,679)
Ending balance, Shares at Jun. 30, 2025	43,850,884		43,850,884
Ending balance at Jun. 30, 2025	$ 262,238		$ 44	$ 687,086	$ (424,892)

Maze Therapeutics, Inc. 10-Q